Immuneering (IMRX)
(Delayed Data from NSDQ)
$1.20 USD
+0.09 (8.11%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Immuneering Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 86 | 106 | 149 | 37 | -99,999 |
Receivables | 0 | 0 | 0 | 1 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 3 | 3 | 0 | NA |
Total Current Assets | 89 | 109 | 152 | 38 | NA |
Net Property & Equipment | 1 | 1 | 1 | 0 | NA |
Investments & Advances | 0 | 0 | 1 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 7 | 7 | 7 | 0 | NA |
Deposits & Other Assets | 1 | 1 | 0 | 0 | NA |
Total Assets | 103 | 122 | 167 | 38 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 3 | 1 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 5 | 5 | 4 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 8 | 8 | 6 | 2 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 58 | NA |
Total Liabilities | 12 | 13 | 11 | 61 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 254 | 220 | 215 | 3 | NA |
Retained Earnings | -163 | -110 | -59 | -26 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 91 | 110 | 156 | -22 | NA |
Total Liabilities & Shareholder's Equity | 103 | 122 | 167 | 38 | NA |
Total Common Equity | 91 | 110 | 156 | -22 | 0 |
Shares Outstanding | 29.20 | 26.40 | 25.90 | NA | NA |
Book Value Per Share | 3.10 | 4.16 | 6.02 | 0.00 | 0.00 |
Fiscal Year End for Immuneering Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 71 | 86 | 97 | 109 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 3 | 3 |
Total Current Assets | NA | 74 | 89 | 101 | 112 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 7 | 7 | 7 | 7 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 88 | 103 | 114 | 125 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 5 | 3 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 5 | 8 | 6 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 9 | 12 | 10 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 256 | 254 | 252 | 251 |
Retained Earnings | NA | -178 | -163 | -148 | -136 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 79 | 91 | 104 | 115 |
Total Liabilities & Shareholder's Equity | NA | 88 | 103 | 114 | 125 |
Total Common Equity | 0 | 79 | 91 | 104 | 115 |
Shares Outstanding | 29.60 | 29.60 | 29.20 | 29.20 | 29.20 |
Book Value Per Share | 0.00 | 2.66 | 3.10 | 3.56 | 3.94 |